Does sequencing order of antiandrogens in prostate cancer matter?

Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer

(2019) Pedro Isaacsson Velho et al.   EUROPEAN UROLOGY

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

(2019) Ronald de Wit et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial

(2019) Daniel J Khalaf et al.   LANCET ONCOLOGY

Hormonal Therapy or Chemotherapy for Metastatic Prostate Cancer — Playing the Right CARD

(2019) Mario A. Eisenberger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel

(2018) Lauren C. Harshman et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

(2018) Matti Annala et al.   Cancer Discovery

Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration

(2017) Naoki Terada et al.   INTERNATIONAL JOURNAL OF UROLOGY

Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis

(2015) Klaus Brasso et al.   EUROPEAN UROLOGY

Androgen pathway resistance in prostate cancer and therapeutic implications

(2015) Benjamin L Maughan et al.   EXPERT OPINION ON PHARMACOTHERAPY